Portal de Periódicos da CAPES

Development of a combination chemotherapy program for adult acute leukemia: CAM and CAM-L

1973; Wiley; Volume: 32; Issue: 1 Linguagem: Inglês

10.1002/1097-0142(197307)32

1097-0142

Roland T. Skeel, John C. Marsh, Ronald C. DeConti, Malcolm S. Mitchell, S M Hubbard, Joseph R. Bertino,

Neutropenia and Cancer Infections

CancerVolume 32, Issue 1 p. 76-81 ArticleFree Access Development of a combination chemotherapy program for adult acute leukemia: CAM and CAM-L Dr. Roland T. Skeel MD, Corresponding Author Dr. Roland T. Skeel MD Assistant Professor of Medicine Yale University School of MedicineDepartment of Internal Medicine, Yale University School of Medicine, 333 Cedar St., New Haven, Conn. 06510===Search for more papers by this authorJohn C. Marsh MD, John C. Marsh MD Associate Professor of Medicine and Pharmacology Yale University School of MedicineSearch for more papers by this authorRonald C. Deconti MD, Ronald C. Deconti MD Assistant Professor of Medicine and Pharmacology Yale University School of MedicineSearch for more papers by this authorMalcolm S. Mitchell MD, Malcolm S. Mitchell MD Assistant Professor of Medicine and Pharmacology Yale University School of MedicineSearch for more papers by this authorSusan Hubbard RN, Susan Hubbard RN Special Procedures Nurse of the Chemotherapy Section, Yale University School of MedicineSearch for more papers by this authorJoseph R. Bertino MD, Joseph R. Bertino MD Professor of Medicine and Pharmacology; Chief Section of Oncology and Cancer Chemotherapy, Yale University School of MedicineSearch for more papers by this author Dr. Roland T. Skeel MD, Corresponding Author Dr. Roland T. Skeel MD Assistant Professor of Medicine Yale University School of MedicineDepartment of Internal Medicine, Yale University School of Medicine, 333 Cedar St., New Haven, Conn. 06510===Search for more papers by this authorJohn C. Marsh MD, John C. Marsh MD Associate Professor of Medicine and Pharmacology Yale University School of MedicineSearch for more papers by this authorRonald C. Deconti MD, Ronald C. Deconti MD Assistant Professor of Medicine and Pharmacology Yale University School of MedicineSearch for more papers by this authorMalcolm S. Mitchell MD, Malcolm S. Mitchell MD Assistant Professor of Medicine and Pharmacology Yale University School of MedicineSearch for more papers by this authorSusan Hubbard RN, Susan Hubbard RN Special Procedures Nurse of the Chemotherapy Section, Yale University School of MedicineSearch for more papers by this authorJoseph R. Bertino MD, Joseph R. Bertino MD Professor of Medicine and Pharmacology; Chief Section of Oncology and Cancer Chemotherapy, Yale University School of MedicineSearch for more papers by this author First published: July 1973 https://doi.org/10.1002/1097-0142(197307)32:1 3.0.CO;2-YCitations: 15AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat Abstract A combination chemotherapy program for the treatment of adult acute myelogenous leukemia (AML) and acute lymphocytic leukemia (ALL) was devised on the basis of theoretical considerations and experimental evidence that a combination of cell cycle-nonspecific and cell cycle-specific agents should be used for induction therapy. The drugs, cyclophosphamide, cytosine arabinoside, and methotrexate, were given as once-weekly pulses until marrow hypoplasia or remission was attained. Complete marrow remissions were achieved in 7 out of 14 patients with AML and 5 out of 8 patients with ALL. Toxicity from the combination was tolerable, although occasionally severe. The induction program compares favorably with other induction regimens in adult acute leukemia, but the short remissions underscore the need for the design of new approaches to improve maintenance therapy. References 1 Bodey, G. P., and Coltman, C. A.: Arabinosyl cytosine (Ara-C) vs. combination chemotherapy (COAP) for adult acute leukemia. Proc. Am. Assoc. Cancer Res. 13: 107 1972 Google Scholar 2 Bodey, G. P., et al.: Protected environment-prophylactic antibiotic program in the chemotherapy of acute leukemia. Am. J. Med. Sci. 262: 138–151 1971 10.1097/00000441-197109000-00001 CASPubMedWeb of Science®Google Scholar 3 Chu, M. Y., and Fischer, G. A.: Effects of Cytosine Arabinoside on the cell viability and uptake of deoxy-pyrimidine Nucleosides in L5178Y cells. Biochem. Pharmacol. 17: 741–751 1968 10.1016/0006-2952(68)90011-7 CASPubMedWeb of Science®Google Scholar 4 Clarkson, B., et al.: Studies of cellular proliferation in human leukemia. III. Behavior of leukemic cells in three adults with acute leukemia given continuous infusions of 3H-thymidine for 8 or 10 days. Cancer 25: 1237–1260 1970 10.1002/1097-0142(197006)25:6 3.0.CO;2-7 CASPubMedWeb of Science®Google Scholar 5 Crowther, D., et al.: Combination chemotherapy using L-asparaginase, daunorubicin, and cytosine arabinoside in adults with acute myelogenous leukemia. Br. Med. J. 4: 513–517 1970 10.1136/bmj.4.5734.513 CASPubMedWeb of Science®Google Scholar 6 Frei, E. III.: Acute granulocytic leukemia in adults. Ar. Engl. J. Med. 286: 1211–1212 1972 10.1056/NEJM197206012862210 PubMedWeb of Science®Google Scholar 7 Gee, T. S., Yu, K. P., and Clarkson, B. D.: Treatment of adult acute leukemia with arabinosylcytosine and thioguanine. Cancer 23: 1019–1032 1969 10.1002/1097-0142(196905)23:5 3.0.CO;2-N CASPubMedWeb of Science®Google Scholar 8 Goldin, A., Venditti, J. M., and Humphreys, S. R.: Modification of treatment schedules in the management of advanced mousee leukemia with amethopterin. J. Natl. Cancer Inst. 17: 203–212 1956 CASPubMedWeb of Science®Google Scholar 9 Henderson, E. S.: Treatment of acute leukemia. Semin. Hematol. 6: 271–319 1969 CASPubMedWeb of Science®Google Scholar 10 Hoffman, G. S., et al.: Sequential chemotherapy with cyclophosphamide (NCS 26 271) and cytosine arabinoside (NCS 63878) in mice with advanced leukemia L1210. Cancer Chemother. Rep. 53: 265–271 1969 CASPubMedWeb of Science®Google Scholar 11 Hryniuk, W. M., and Bertino, J. R.: Treatment of leukemia with large doses of methotrexate and folinic acid: Clinical-biochemical correlates. J. Clin. Invest. 48: 2140–2145 1969 10.1172/JCI106181 CASPubMedWeb of Science®Google Scholar 12 Hryniuk, W. M., Fischer, G. A., and Bertino, J. R.: S-phase cells of rapidly growing and resting populations. Differences in response to methotrexate. Mol. Pharmacol. 5: 557–564 1969 CASPubMedWeb of Science®Google Scholar 13 Levi, J. A., Vincent, P. C., and Gunz, F. W.: Combination chemotherapy of adult acute nonlymphoblastic leukemia. Ann. Intern. Med. 76: 397–403 1972 10.7326/0003-4819-76-3-397 CASPubMedWeb of Science®Google Scholar 14 Levitt, M., et al.: Combination sequential chemotherapy in advanced reticulum cell sarcoma. Cancer 29: 630–636 1972 10.1002/1097-0142(197203)29:3 3.0.CO;2-Q CASPubMedWeb of Science®Google Scholar 15 Perillie, P. E., et al.: Studies of murimadase (lysozyme) in leukemia. JAMA 203: 317–322. 1968. 10.1001/jama.1968.03140050001001 Web of Science®Google Scholar 16 Rosenthal, D. S., and Moloney, W. C.: The treatment of acute granulocytic leukemia in adults. N. Engl. J. Med. 286: 1176–1178 1972 10.1056/NEJM197206012862202 CASPubMedWeb of Science®Google Scholar 17 Schabel, F. M., Jr.: The use tumor growth kinetics in planning “curative” chemotherapy of advanced solid tumors. Cancer Res. 29: 2384–2389 1969 PubMedWeb of Science®Google Scholar 18 Skipper, H. E., et al.: Response to therapy of spontaneous, first passage and long passage, lines of AK leukemia. Cancer Chemother. Rep. 53: 345–364 1969 CASPubMedWeb of Science®Google Scholar 19 Benditti, J. M., and Goldin, A.: Chemotherapy of advanced mouse leukemia L 1210 Comparison of methotrexate alone and in sequential therapy. Cancer Res. 24: 1457–1460 1966 PubMedWeb of Science®Google Scholar Citing Literature Volume32, Issue1July 1973Pages 76-81 ReferencesRelatedInformation